Anthropic’s Strategic Acquisition of Coefficient Bio: A $400 Million Leap into Biotech AI
In a significant move that underscores its commitment to integrating artificial intelligence (AI) into the life sciences sector, Anthropic has acquired the stealth-mode biotech AI startup Coefficient Bio in a stock deal valued at $400 million. This acquisition, reported by The Information and Eric Newcomer, has been confirmed by sources close to the deal, though they declined to comment on the exact amount.
Anthropic’s Foray into Healthcare and Life Sciences
This acquisition aligns with Anthropic’s ongoing efforts to expand its footprint in healthcare and life sciences. In October 2025, the company introduced Claude for Life Sciences, an AI tool designed to assist scientific researchers in making groundbreaking discoveries. The addition of Coefficient Bio’s expertise is expected to bolster Anthropic’s capabilities in this domain.
About Coefficient Bio
Founded just eight months ago by Samuel Stanton and Nathan C. Frey, Coefficient Bio has been operating in stealth mode. Both founders have a background in computational drug discovery, having previously worked at Genentech’s Prescient Design. Coefficient Bio’s mission has been to leverage AI to enhance the efficiency of drug discovery and other biological research processes. The startup’s team, comprising approximately ten individuals, is anticipated to join Anthropic’s health and life sciences division.
Anthropic’s Growth Trajectory
Anthropic’s acquisition of Coefficient Bio is part of a broader strategy to integrate AI into various sectors. In February 2026, the company raised an additional $30 billion in a Series G funding round, elevating its valuation to $380 billion. This funding round was led by Singaporean wealth fund GIC and investment management firm Coatue, with participation from other prominent investors such as D. E. Shaw Ventures, Peter Thiel’s Founders Fund, and Abu Dhabi’s MGX.
Strategic Partnerships and Investments
Anthropic has been actively forming strategic partnerships to enhance its AI capabilities. In November 2024, the company secured an additional $4 billion investment from Amazon, designating Amazon Web Services (AWS) as its primary training partner. This collaboration includes working with AWS’s chipmaking division, Annapurna Labs, to develop future generations of Trainium accelerators, AWS’s custom-built chips for training AI models.
Expansion into Scientific Research
In May 2025, Anthropic launched an AI for Science program aimed at supporting researchers working on high-impact scientific projects, particularly in biology and life sciences. The program offers up to $20,000 in Anthropic API credits over a six-month period to qualified researchers, providing access to Anthropic’s suite of AI models, including the Claude family.
Anthropic’s Commitment to AI Safety and Governance
Anthropic has also demonstrated a commitment to AI safety and governance. In June 2025, the company appointed Richard Fontaine, a national security expert, to its long-term benefit trust. This governance mechanism is designed to promote safety over profit and has the authority to elect some of the company’s board of directors.
Conclusion
The acquisition of Coefficient Bio represents a strategic step for Anthropic as it continues to integrate AI into the life sciences sector. By combining Coefficient Bio’s expertise in computational drug discovery with Anthropic’s advanced AI capabilities, the company is well-positioned to drive innovation in healthcare and biological research. This move reflects Anthropic’s broader strategy of expanding its AI applications across various industries, supported by significant investments and strategic partnerships.
